Understanding how the immune system fights FLT3-ITD Acute Myeloid Leukemia
Leveraging the TCR Repertoire to identify target neoantigens in FLT3-ITD positive Acute Myeloid Leukemia
['FUNDING_R01'] · UNIVERSITY OF SOUTHERN CALIFORNIA · NIH-11093985
This project aims to understand how a patient's immune system, specifically T-cells, can recognize and fight acute myeloid leukemia (AML) with a specific FLT3-ITD mutation after a stem cell transplant.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF SOUTHERN CALIFORNIA (nih funded) |
| Locations | 1 site (Los Angeles, UNITED STATES) |
| Trial ID | NIH-11093985 on ClinicalTrials.gov |
What this research studies
For patients with high-risk acute myeloid leukemia (AML), a stem cell transplant is often the best chance for a cure. However, complications like graft-versus-host disease or the leukemia returning can affect success. This project looks closely at the immune cells called T-cells from patients who have received a transplant, especially those with a specific FLT3-ITD mutation in their AML. By studying how these T-cells recognize and target the leukemia, we hope to find new ways to make transplants more effective and reduce complications. The goal is to identify specific markers on leukemia cells that the immune system can attack.
Who could benefit from this research
Good fit: Patients with FLT3-ITD positive Acute Myeloid Leukemia who have undergone or are candidates for allogeneic hematopoietic stem cell transplantation are the focus of this research.
Not a fit: Patients with other types of leukemia or those not undergoing stem cell transplantation may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new ways to improve the effectiveness of stem cell transplants for AML patients, potentially by guiding immune therapies or reducing complications.
How similar studies have performed: While the role of T-cells in transplant outcomes is known, this specific approach of leveraging the TCR repertoire to identify neoantigens in FLT3-ITD positive AML is a novel and detailed investigation.
Where this research is happening
Los Angeles, UNITED STATES
- UNIVERSITY OF SOUTHERN CALIFORNIA — Los Angeles, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ALACHKAR, HOUDA — UNIVERSITY OF SOUTHERN CALIFORNIA
- Study coordinator: ALACHKAR, HOUDA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.